MINNEAPOLIS--(BUSINESS WIRE)--Further demonstrating its commitment to proving the benefits of minimally-invasive procedures, Medtronic, Inc. (NYSE: MDT), today announced that the first patient has been treated with the company’s Valiant® Thoracic Stent Graft with the Captivia Delivery System in Medtronic’s RESCUE Clinical Study.
